top of page

VACCINES FOR PANDEMIC PREPAREDNESS

Designing and developing efficient vaccines that can be used to rapidly respond to pandemic emergencies. 

TECHNOLOGY

SELF-ASSEMBLING PROTEIN NANOPARTICLES

B-CELL IMMUNE RESPONSE

 

Self-Assembling Protein Nanoparticles (SAPNs) induce a strong B-cell immune response based on their repetitive display of B-cell epitopes.

T-CELL IMMUNE RESPONSE

 

SAPNs induce a strong T-cell immune response based on the incorporated T-cell epitopes.

INNATE IMMUNE RESPONSE

 

SAPNs trigger a strong innate immune response based on their built-in adjuvant molecules.

Technology

INDICATIONS

1. Influenza

Despite the many available seasonal flu vaccines, influenza remains one of the most dangerous public health challenges. While already the regular seasonal influenza epidemics are usually of considerable impact for the public health system, the irregularly occurring influenza pandemics, which can cause high levels of mortality remain a very serious threat. The “Spanish flu” in 1918 killed about 50 to 100 million people and in each of the last three centuries there has been about three influenza pandemics, and the most recent one (even though very mild in its appearance) occurred in 2009. One of the reasons for the danger of a potential influenza pandemic is the very high transmission rate of the influenza virus, leading to the rapid spread of the disease. Hence pandemic preparedness and readiness for influenza outbreaks need to be as rapid as humanly possible. (publications)

2. COVID-19

COVID-19 (Coronavirus disease 2019) is a rapidly ​spreading viral disease caused by the virus SARS CoV-2. The outbreak occurred in Mainland China late in 2019 and has ever since affected most countries of the world. People develop flu-like symptoms and if disease progression is severe they may die from pneumonia or multi-organ failure. As of February 20, 2020 the estimated case fatality rate (CFR) was 2.8%. Since the transmission rate (currently estimated at 2 – 3) is even much higher than for influenza it will be very hard to contain the virus and unfortunately a pandemic is a quite likely scenario. More than 200 countries have already been affected and hence a vaccine is desperately needed. (publications)

indications

OUR PEOPLE

KarchPicture_edited.jpg
Christopher Karch
CEO
Sharareh-Emadi.jpg
Sharareh Emadi
CSO
BurkhardPicture.JPG
Peter Burkhard
COO
Kamal_ElBissati.png
Kamal El Bissati 
Head Vaccine Development
People

CONTACT

YCOCEDRON

OUR ADDRESS

Ycocedron Inc., 1376 Storrs Road, U-4090, Storrs, Connecticut 06268

Email: contact@ycocedron.com
Tel:  123-456-7890

 

Click Here to Find Us

For any general inquiries, please fill in the following contact form:

Success! Message received.

contact

© 2020 by Ycocedron Inc.

bottom of page